OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on April 5, 2016, covering events occurring on April 1, 2016. The filing addresses the status of the Company's 3.0% Convertible Senior Notes due 2033.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific debt and liquidity metrics related to the convertible notes are as follows:
- Outstanding Notes: $32.2 million principal amount.
- Conversion Price: $7.07 per share.
- Trigger Threshold: 130% of conversion price ($9.19).
- Conversion Rate: 141.4827 shares of Common Stock per $1,000 principal amount, plus applicable additional shares under early conversion provisions.
Material Changes
The Company determined that the conversion right for the Notes has been extended through June 30, 2016. This extension was triggered because the closing price of the Company's Common Stock exceeded $9.19 for at least 20 of 30 consecutive trading days during the quarter ended March 31, 2016. This condition has also been met in the four preceding quarters (ended March 31, 2015, through December 31, 2015).
Outlook, Risks, and Management Commentary
The Company has elected to satisfy its conversion obligation in shares of Common Stock. The Notes will remain convertible until June 30, 2016, and may remain convertible thereafter if specific conditions in the Indenture are satisfied during future measurement periods. Wells Fargo Bank, National Association serves as the trustee and conversion agent.
Key Facts for Investor Verification
- Verify the current trading price of OPKO Health Common Stock relative to the $9.19 threshold to assess the likelihood of continued convertibility beyond June 30, 2016.
- Confirm the exact number of shares to be issued upon conversion, as this includes variable additional shares based on early conversion provisions.
- Review the Indenture dated January 30, 2013, for specific mechanics regarding the conversion process and future measurement periods.
- Monitor potential dilution impact on existing shareholders given the $32.2 million principal amount outstanding.